In this webinar, the following aspects will be presented:

• What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques?
• What are some techniques that may be used to understand the origins of resistance selection?
• How to rationalize/manage the risk of translation of the resistance selection from in vitro to the clinical settings?

The presentation will be followed by a Q&A session.

This presentation was also part of the ‘Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process’, jointly organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019. 

Speaker: Michael Mourez, Head BacteriOmics Platform, Evotec (France)

Moderator: Laura Piddock, Director Scientific Affairs, GARDP

Register here for this live webinar.